FDA Authorizes Importation of Tentatively-Approved Narcolepsy Drug
The authorization allows the company to shorten the time to product availability following an anticipated final approval decision from the FDA.
Category: Narcolepsy
Narcolepsy
Latest
Narcolepsy
Latest
FDA Data Captures Dosing Errors with Twice-Nightly Oxybates for Narcolepsy
Investigators affiliated with Avadel Pharmaceuticals plc published a paper describing the risk of accidental dosing errors with oxybate.
Narcolepsy
Latest
FDA Gives Tentative Approval to LUMRYZ, Avadel’s Narcolepsy Drug
The US Food and Drug Administration has granted tentative approval to LUMRYZ, also known as FT218, by Avadel Pharmaceuticals plc.
The Three Most Common Comorbidities in People with Narcolepsy
Two of the three narcolepsy comorbidities are well documented, but the third is likely new information for many physicians and patients.
Read More
Tris Pharma Is Working on a Low Sodium, Once-Nightly Oxybate Formulation for Narcolepsy
Tris has developed an oxybate formulation intended for the treatment of cataplexy or excessive daytime sleepiness in people with narcolepsy.
Read More
Harmony Biosciences Announces 2022 Funding Recipients of Patients at the Heart And Progress at the Heart Award Programs
Harmony Biosciences Holdings Inc revealed the funding recipients of its Patients at the Heart and Progress at the Heart award programs.
Read More
Knowledge Gaps Exist Even Among Physicians Treat Narcolepsy
Wake Up Narcolepsy revealed results of a survey of 100 physicians who treat narcolepsy in children and adolescents in the Greater Boston Area.
Read More
Scientists Win Breakthrough Prize for Discovering the Cause of Narcolepsy
Each year, the Breakthrough Prize awards $15 million across five prizes to top researchers working in the fields of physics, mathematics and life sciences.
Read More
Could a History of Depression Change Outcomes for Sleep Apnea Patients Treated for EDS?
New research looked at whether a history of depression changed outcomes in patients with sleep apnea or narcolepsy who use solriamfetol to control excessive daytime sleepiness.
Read More
How to Manage Psychosocial Challenges of Pediatric Narcolepsy
Experts share tips on how to provide comprehensive narcolepsy treatment for children using an interdisciplinary care approach.
Read More
Camp for Children with Narcolepsy Aims to Connect Families
Sponsored by the not-for-profit organization Wake Up Narcolepsy, the camp will take place over a weekend in late September.
Read More
Harmony Biosciences Presents Post-Hoc Analysis Of WAKIX Pivotal Data In Adults With High Burden Of Narcolepsy Symptoms
A SLEEP 2022 poster presents a post-hoc analysis of pooled data from patients in WAKIX pivotal clinical trials who had a high burden of narcolepsy.
Read More
Axsome Completes US Acquisition of Sunosi
‘The Sunosi acquisition marks the transformation of Axsome into a commercial neuroscience company and reflects our commitment to the millions of people living with serious neurologic and psychiatric conditions.’
Read More
Jazz Pharmaceuticals Gets Development Rights to Orexin-2 Receptor Agonist with Treatment Potential for Narcolepsy, IH, and More
Jazz Pharmaceuticals has acquired development and commercialization rights in the United States for Sumitomo’s investigational DSP-0187.
Read More
‘Take the Nap Before the Nap Takes You’: 5 Perspectives on Napping for Narcolepsy Patients
Exactly how, when, and for how long a person with narcolepsy should nap to manage their disorder varies. Sleep physicians, patients, and advocates detail the nuances of how to navigate scheduled daytime sleep.
Read More
More Than Half of People with Narcolepsy Report Missing Second Dose of Twice-Nightly Oxybate Therapy
‘The results from the nocturnal adverse event questionnaire illustrate the burden that the second dose places on some patients.’
Read More
‘My Struggle With Narcolepsy’
A patient describes their narcolepsy diagnosis story and the struggle with daytime sleepiness that led to a car accident.
Read More
Understanding the Cardiovascular Burden Among Patients With Narcolepsy
Cardiovascular risk profiles should be taken into account when weighing risk modification strategies and making treatment decisions for patients with narcolepsy, according to study results presented at the 2022 American Academy of Neurology Annual Meeting.
Read More